U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H30FN7O
Molecular Weight 451.5406
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CENISERTIB

SMILES

Cc1cc(ccc1N2CCN(C)CC2)Nc3ncc(c(=N[C@]4([H])[C@@]5([H])C=C[C@]([H])(C5)[C@]4([H])C(=N)O)[nH]3)F

InChI

InChIKey=KSOVGRCOLZZTPF-QMKUDKLTSA-N
InChI=1S/C24H30FN7O/c1-14-11-17(5-6-19(14)32-9-7-31(2)8-10-32)28-24-27-13-18(25)23(30-24)29-21-16-4-3-15(12-16)20(21)22(26)33/h3-6,11,13,15-16,20-21H,7-10,12H2,1-2H3,(H2,26,33)(H2,27,28,29,30)/t15-,16+,20+,21-/m1/s1

HIDE SMILES / InChI

Molecular Formula C24H30FN7O
Molecular Weight 451.5406
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Cenisertib (also known as R763) is water-soluble, synthetic small molecule aurora kinase inhibitor with potential antineoplastic activity. Cenisertib is a potent adenine triphosphate-competitive inhibitor of Aurora kinase isoforms A–C, disrupting mitotic spindle activity, blocking cell separation, and leading to polyploidy and cell death. At low nanomolar concentrations, Cenisertib also inhibits other kinases involved in cell survival and proliferation including FLT3, BCR-ABL1, and BCR-ABL1 with T315I mutation. It also inhibits JAK2 kinase, but at higher concentrations. Preclinically, Cenisertib has demonstrated potent antitumor activity as a single agent and in combination treatment in leukemia cell lines, freshly isolated leukemia cells, and leukemia xenograft models. Toxicities appear to be related mainly to the gastrointestinal and hematopoietic systems. In animal models, activity and toxicity depend not only on dose but also on the schedule of administration.

Approval Year

PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Patients received escalating doses either on days 1–3 and 8–10 (n = 36) or on days 1–6 (n = 39) of a 21-day cycle. The maximum tolerated doses were 37 and 28 mg/m2/day, respectively.
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Sat Jun 26 09:23:37 UTC 2021
Edited
by admin
on Sat Jun 26 09:23:37 UTC 2021
Record UNII
5277GPA358
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CENISERTIB
INN   WHO-DD  
INN  
Official Name English
R-763
Common Name English
BICYCLO(2.2.1)HEPT-5-ENE-2-CARBOXAMIDE, 3-((5-FLUORO-2-((3-METHYL-4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-4-PYRIMIDINYL)AMINO)-, (1S,2S,3R,4R)-
Systematic Name English
AURORA KINASE INHIBITOR AS703569
Common Name English
R 763
Code English
AS703569
Code English
CENISERTIB [WHO-DD]
Common Name English
(1S,2S,3R,4R)-3-((5-FLUORO-2-((3-METHYL-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO)PYRIMIDIN-4-YL)AMINO)BICYCLO(2.2.1)HEPT-5-ENE-2-CARBOXAMIDE
Systematic Name English
AS 703569
Code English
AS-703569
Code English
CENISERTIB [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C62556
Created by admin on Sat Jun 26 09:23:38 UTC 2021 , Edited by admin on Sat Jun 26 09:23:38 UTC 2021
NCI_THESAURUS C129825
Created by admin on Sat Jun 26 09:23:38 UTC 2021 , Edited by admin on Sat Jun 26 09:23:38 UTC 2021
Code System Code Type Description
CAS
871357-89-0
Created by admin on Sat Jun 26 09:23:38 UTC 2021 , Edited by admin on Sat Jun 26 09:23:38 UTC 2021
PRIMARY
PUBCHEM
11569967
Created by admin on Sat Jun 26 09:23:38 UTC 2021 , Edited by admin on Sat Jun 26 09:23:38 UTC 2021
PRIMARY
EPA CompTox
871357-89-0
Created by admin on Sat Jun 26 09:23:38 UTC 2021 , Edited by admin on Sat Jun 26 09:23:38 UTC 2021
PRIMARY
DRUG BANK
DB06347
Created by admin on Sat Jun 26 09:23:38 UTC 2021 , Edited by admin on Sat Jun 26 09:23:38 UTC 2021
PRIMARY
ChEMBL
CHEMBL1967878
Created by admin on Sat Jun 26 09:23:38 UTC 2021 , Edited by admin on Sat Jun 26 09:23:38 UTC 2021
PRIMARY
NCI_THESAURUS
C64540
Created by admin on Sat Jun 26 09:23:38 UTC 2021 , Edited by admin on Sat Jun 26 09:23:38 UTC 2021
PRIMARY
EVMPD
SUB129550
Created by admin on Sat Jun 26 09:23:38 UTC 2021 , Edited by admin on Sat Jun 26 09:23:38 UTC 2021
PRIMARY
INN
9355
Created by admin on Sat Jun 26 09:23:38 UTC 2021 , Edited by admin on Sat Jun 26 09:23:38 UTC 2021
PRIMARY
FDA UNII
5277GPA358
Created by admin on Sat Jun 26 09:23:38 UTC 2021 , Edited by admin on Sat Jun 26 09:23:38 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY